Relevant bibliographies by topics / Matrix-M adjuvant

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters

Academic literature on the topic 'Matrix-M adjuvant'

Author: Grafiati
Published: 7 June 2025
Last updated: 16 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Matrix-M adjuvant.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Matrix-M adjuvant"

1

Bengtsson, Karin Lövgren, Haifeng Song, Linda Stertman, et al. "Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice." Vaccine 34, no. 16 (2016): 1927–35. https://doi.org/10.5281/zenodo.14822462.

Full text
Abstract:
(Uploaded by Plazi for the Bat Literature Project) Ebola virus (EBOV) causes severe hemorrhagic fever for which there is no approved treatment or preventive vaccine. Immunological correlates of protective immunity against EBOV disease are not well understood. However, non-human primate studies have associated protection of experimental vaccines with binding and neutralizing antibodies to the EBOV glycoprotein (GP) as well as EBOV GP-specific CD4+ and CD8+ T cells. In this report a full length, unmodified Zaire EBOV GP gene from the 2014 EBOV Makona strain (EBOV/Mak) was cloned into a baculovirus vector. Recombinant EBOV/Mak GP was produced in Sf9 insect cells as glycosylated trimers and, when purified, formed spherical 30–40nm particles. In mice, EBOV/Mak GP co-administered with the saponin adjuvant Matrix-M was significantly more immunogenic, as measured by virus neutralization titers and anti-EBOV/Mak GP IgG as compared to immunization with AlPO4 adjuvanted or non-adjuvanted EBOV/Mak GP. Similarly, antigen specific T cells secreting IFN-γ were induced most prominently by EBOV/Mak GP with Matrix-M. Matrix-M also enhanced the frequency of antigen-specific germinal center B cells and follicular helper T (TFH) cells in the spleen in a dose-dependent manner. Immunization with EBOV/Mak GP with Matrix-M was 100% protective in a lethal viral challenge murine model; whereas no protection was observed with the AlPO4 adjuvant and only 10% (1/10) mice were protected in the EBOV/Mak GP antigen alone group. Matrix-M adjuvanted vaccine induced a rapid onset of specific IgG and neutralizing antibodies, increased frequency of multifunctional CD4+ and CD8+ T cells, specific TFH cells, germinal center B cells, and persistence of EBOV GP-specific plasma B cells in the bone marrow. Taken together, the addition of Matrix-M adjuvant to the EBOV/Mak GP nanoparticles enhanced both B and T-cell immune stimulation which may be critical for an Ebola subunit vaccine with broad and long lasting protective immunity.
APA, Harvard, Vancouver, ISO, and other styles
2

Fossum, Caroline, Bernt Hjertner, Viktor Ahlberg, et al. "Early inflammatory response to the saponin adjuvant Matrix-M in the pig." Veterinary Immunology and Immunopathology 158, no. 1-2 (2014): 53–61. http://dx.doi.org/10.1016/j.vetimm.2013.07.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fries, Louis, Iksung Cho, Verena Krähling, et al. "Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults." Journal of Infectious Diseases 222, no. 4 (2019): 572–82. http://dx.doi.org/10.1093/infdis/jiz518.

Full text
Abstract:
Abstract Background Ebola virus (EBOV) epidemics pose a major public health risk. There currently is no licensed human vaccine against EBOV. The safety and immunogenicity of a recombinant EBOV glycoprotein (GP) nanoparticle vaccine formulated with or without Matrix-M adjuvant were evaluated to support vaccine development. Methods A phase 1, placebo-controlled, dose-escalation trial was conducted in 230 healthy adults to evaluate 4 EBOV GP antigen doses as single- or 2-dose regimens with or without adjuvant. Safety and immunogenicity were assessed through 1-year postdosing. Results All EBOV GP vaccine formulations were well tolerated. Receipt of 2 doses of EBOV GP with adjuvant showed a rapid increase in anti-EBOV GP immunoglobulin G titers with peak titers observed on Day 35 representing 498- to 754-fold increases from baseline; no evidence of an antigen dose response was observed. Serum EBOV-neutralizing and binding antibodies using wild-type Zaire EBOV (ZEBOV) or pseudovirion assays were 3- to 9-fold higher among recipients of 2-dose EBOV GP with adjuvant, compared with placebo on Day 35, which persisted through 1 year. Conclusions Ebola virus GP vaccine with Matrix-M adjuvant is well tolerated and elicits a robust and persistent immune response. These data suggest that further development of this candidate vaccine for prevention of EBOV disease is warranted.
APA, Harvard, Vancouver, ISO, and other styles
4

Lee, Alexander, Shane Larson, Veronica Zielinski, Deborah Long, Jessica Flechtner, and Mojca Skoberne. "HSV-2 antigens formulated with Matrix M-2 induce balanced neutralizing antibody and durable polyfunctional T cell responses in mice (113.5)." Journal of Immunology 188, no. 1_Supplement (2012): 113.5. http://dx.doi.org/10.4049/jimmunol.188.supp.113.5.

Full text
Abstract:
Abstract An effective HSV-2 vaccine is still needed despite the prevalence of antiviral drugs. Recent HSV-2 vaccine clinical trials highlighted the need to elicit potent T cell responses since neutralizing antibodies alone were incapable of providing complete protection. Through proteomic screens using T cells of HSV-2-exposed donors several antigens were identified as promising vaccine targets. Two of these antigens, GB208 and GB217 (GEN-003), were formulated with a saponin-derived adjuvant Matrix M-2, which in recent avian influenza human clinical trials induced cellular and humoral immune responses. In preclinical studies, C57BL/6 mice were used to evaluate the ability of GEN-003 combined with Matrix M-2 to induce antigen-specific T cell and antibody responses. T cell effector functions were evaluated by IFNγ ELISPOT, intracellular cytokine staining, and in vivo cytolysis of fluorescently labeled peptide-pulsed targets. Neutralizing antibody responses as well as total and subclass IgG titers were also assessed. Cellular and humoral immune responses were primed in mice after administering a wide range of protein and adjuvant doses. GB208- and GB217- specific T cell responses were polyfunctional, cytolytic, and persisted for more than 3 months. Antibody responses were neutralizing, and represented balanced Th1/Th2 phenotypes. In conclusion, GEN-003 combined with Matrix M-2 form a promising vaccine candidate that activates both arms of the immune system necessary for viral clearance.
APA, Harvard, Vancouver, ISO, and other styles
5

Lövgren Bengtsson, Karin, Bror Morein, and Albert DME Osterhaus. "ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation." Expert Review of Vaccines 10, no. 4 (2011): 401–3. http://dx.doi.org/10.1586/erv.11.25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bengtsson, Karin Lövgren, Karin H. Karlsson, Sofia E. Magnusson, Jenny M. Reimer, and Linda Stertman. "Matrix-M™ adjuvant: enhancing immune responses by ‘setting the stage’ for the antigen." Expert Review of Vaccines 12, no. 8 (2013): 821–23. http://dx.doi.org/10.1586/14760584.2013.814822.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cox, Rebecca J., Gabriel Pedersen, Abdullah S. Madhun, et al. "Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial." Vaccine 29, no. 45 (2011): 8049–59. http://dx.doi.org/10.1016/j.vaccine.2011.08.042.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Reimer, Jenny M., Karin H. Karlsson, Karin Lövgren-Bengtsson, Sofia E. Magnusson, Alexis Fuentes, and Linda Stertman. "Matrix-M™ Adjuvant Induces Local Recruitment, Activation and Maturation of Central Immune Cells in Absence of Antigen." PLoS ONE 7, no. 7 (2012): e41451. http://dx.doi.org/10.1371/journal.pone.0041451.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sang, Samuel, Mehreen S. Datoo, Edward Otieno, et al. "Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya." Wellcome Open Research 8 (October 12, 2023): 450. http://dx.doi.org/10.12688/wellcomeopenres.19795.1.

Full text
Abstract:
Background: Falciparum malaria remains a global health problem. Two vaccines, based on the circumsporozoite antigen, are available. RTS, S/AS01 was recommended for use in 2021 following the advice of the World Health Organisation (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization and WHO Malaria Policy Advisory Group (MPAG). It has since been pre-qualified in 2022 by the WHO. R21 is similar to RTS, S/AS01, and recently licensed in Nigeria, Ghana and Burkina Faso following Phase 3 trial results. Methods: We conducted a Phase 1b age de-escalation, dose escalation bridging study after a change in the manufacturing process for R21. We recruited healthy adults and children and used a three dose primary vaccination series with a booster dose at 1–2 years. Variable doses of R21 and adjuvant (Matrix-M ™) were administered at 10µgR21/50 µg Matrix-M™, 5µgR21/25µg Matrix-M™ and 5µgR21/50µg Matrix-M™ to 20 adults, 20 children, and 51 infants. Results: Self-limiting adverse events were reported relating to the injection site and mild systemic symptoms. Two serious adverse events were reported, neither linked to vaccination. High levels of IgG antibodies to the circumsporozoite antigen were induced, and geometric mean titres in infants, the target group, were 1.1 (0.9 to 1.3) EU/mL at day 0, 10175 (7724 to 13404) EU/mL at day 84 and (following a booster dose at day 421) 6792 (5310 to 8687) EU/mL at day 456. Conclusions: R21/Matrix-M™ is safe, and immunogenic when given at varied doses with the peak immune response seen in infants 28 days after a three dose primary vaccination series given four weeks apart. Antibody responses were restored 28 days after a 4th dose given one year post a three dose primary series in the young children and infants. Registration: Clinicaltrials.gov (NCT03580824; 9th of July 2018; Pan African Clinical Trials Registry (PACTR202105682956280; 17th May 2021).
APA, Harvard, Vancouver, ISO, and other styles
10

Magnusson, Sofia E., Arwen F. Altenburg, Karin Lövgren Bengtsson, et al. "Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice." Immunologic Research 66, no. 2 (2018): 224–33. http://dx.doi.org/10.1007/s12026-018-8991-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Matrix-M adjuvant"

1

Hjälte, Anna, Elin Georgsson, Linus Olausson, Joakim Fichtel, and Viktor Törnblom. "Gamla lösningar på nya problem : Förslag på lösningsmedia för Matrix M™ adjuvans." Thesis, Uppsala universitet, Institutionen för biologisk grundutbildning, 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-176344.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Matrix-M adjuvant"

1

Bengtsson, Karin Lövgren. "Matrix M Adjuvant Technology." In Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines. Springer US, 2012. http://dx.doi.org/10.1007/978-1-4614-5380-2_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Matrix-M adjuvant' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography